NCT05585567View on ClinicalTrials.gov

A Preliminary Exploratory Study to Evaluate the Safety and Immunogenicity of Omicron Variant Bivalent Vaccine V-01-B5

EARLY_PHASE1UnknownINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

September 16, 2022

Primary Completion Date

October 14, 2022

Study Completion Date

September 11, 2023

Conditions
COVID-19 Pandemic
Interventions
BIOLOGICAL

V-01/V-01-B5

Contains 10μg of V-01 and 10μg of V-01-B5

BIOLOGICAL

V-01-351/V-01-B5

Contains 10μg of V-01-351 and 10μg of V-01-B5

BIOLOGICAL

V-01

Contains 10μg of V-01

Trial Locations (1)

512000

Shaoguan Hospital of Chinese Medicine, Shaoguan

Sponsors
All Listed Sponsors
lead

Livzon Pharmaceutical Group Inc.

INDUSTRY